<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081300</url>
  </required_header>
  <id_info>
    <org_study_id>LPCN 1021-13-001</org_study_id>
    <nct_id>NCT02081300</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism</brief_title>
  <acronym>SOAR</acronym>
  <official_title>Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lipocine Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lipocine Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of an oral testosterone
      undecanoate formulation for use as testosterone-replacement therapy in men with low
      testosterone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of LPCN 1021-treated subjects who achieve a total testosterone concentration [Cavg] between 300 - 1140 ng/dL.</measure>
    <time_frame>Following 13 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of LPCN 1021-treated subjects with maximum serum T concentrations (Cmax) values that are (a) less than 1500 ng/dL; (b) between 1800 and 2500 ng/dL, and (c) greater than 2500 ng/dL</measure>
    <time_frame>Following 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient reported outcomes for LPCN 1021 (i.e., International Prostate Symptom Score [I-PSS], Psychosexual Daily Questionnaire [PDQ], Short Form-36 Questionnaire [SF-36])</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 52 weeks in safety laboratory parameters (i.e., clinical chemistry, hematology, PSA)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events during 52 weeks of treatment</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Male Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Oral testosterone undecanoate, LPCN 1021</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical testosterone gel 1.62 %</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral testosterone undecanoate, LPCN 1021</intervention_name>
    <arm_group_label>Oral testosterone undecanoate, LPCN 1021</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical testosterone gel 1.62 %</intervention_name>
    <arm_group_label>Topical testosterone gel 1.62 %</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented diagnosis of primary hypogonadism (congenital or acquired) or
             hypogonadotropic hypogonadism (congenital or acquired).

          2. Serum total testosterone &lt; 300 ng/dL based on 2 consecutive blood samples

        Exclusion Criteria:

        A subject will not be eligible for study participation if he meets any of the following
        criteria.

          1. History of significant sensitivity or allergy to androgens, castor oil or product
             excipients.

          2. Clinically significant findings in the prestudy examinations.

          3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or I-PSS
             score &gt; 19 points.

          4. Body mass index (BMI) â‰¥ 38 kg/m2.

          5. Clinically significant abnormal laboratory values

          6. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B
             surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human
             immunodeficiency virus antibodies (HIV Ab).

          7. History of seizures or convulsions, including febrile, alcohol or drug withdrawal
             seizures.

          8. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical
             procedure that might interfere with gastrointestinal motility, pH or absorption.

          9. History of any clinically significant illness, infection, or surgical procedure within
             1 month prior to study drug administration.

         10. History of stroke or myocardial infarction within the past 5 years.

         11. History of, or current or suspected, prostate or breast cancer.

         12. History of diagnosed, severe, untreated, obstructive sleep apnea.

         13. History of abuse of alcohol or any drug substance in the opinion of the investigator
             within the previous 2 years.

         14. History of long QT syndrome or unexplained sudden death in a first degree relative
             (parent, sibling, or child).

         15. Concurrent treatment with medications which may impact the absorption, distribution,
             metabolism or excretion of testosterone undecanoate (TU) or place the subject at risk
             for treatment with testosterone.

         16. Subject has a partner who is currently pregnant or planning pregnancy during the
             course of the clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony DelConte, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Director, Lipocine, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <disposition_first_submitted>October 19, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 23, 2017</disposition_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Male hypogonadism</keyword>
  <keyword>Low testosterone</keyword>
  <keyword>LPCN 1021</keyword>
  <keyword>Androgel</keyword>
  <keyword>Testim</keyword>
  <keyword>Testopel</keyword>
  <keyword>Fortesta</keyword>
  <keyword>Axiron.</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Eunuchism</keyword>
  <keyword>Gonadal Disorders</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Testosterone enanthate</keyword>
  <keyword>Testosterone undecanoate</keyword>
  <keyword>Testosterone 17 beta-cypionate</keyword>
  <keyword>Methyltestosterone</keyword>
  <keyword>Androgens</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormones, Hormone Substitutes, and Hormone Antagonists</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Antineoplastic Agents, Hormonal</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Anabolic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Hormones, Hormone Substitutes, and Hormone Antagonists</mesh_term>
    <mesh_term>Antineoplastic Agents, Hormonal</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

